Skip to content

Study · Not a test of the peptide alone · 2017

6 results

Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.

Liakopoulou P, Liakos A, Vasilakou D, Athanasiadou E, Bekiari E, Kazakos K, Tsapas A

Endocrine12 Apr 2017Cited by 14 (Europe PMC)

PMID28401444 (opens in a new tab)DOI10.1007/s12020-017-1293-6 (opens in a new tab)PepBankPUB-28401444
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with diabetes, switching from basal insulin to a fixed ratio combination of basal insulin with a GLP-1 receptor agonist was associated with lower haemoglobin A1c in a pooled analysis.

    In plain wordsIn people with diabetes, switching from basal insulin to an insulin plus GLP-1 drug combination was linked to lower HbA1c.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change after switch from basal insulin to fixed ratio combination
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Switch from basal insulin to fixed ratio combinations with a glucagon like peptide 1 receptor agonist was associated with 0.72% reduction in haemoglobin A1c [95% confidence interval -1.03 to -0.41; I 2 = 93%]
    1 context sentence
    Summary · context
    We conducted a systematic review and meta-analysis of randomised controlled trials to investigate the efficacy and safety of fixed ratio combinations of basal insulin with glucagon like peptide 1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with diabetes, switching from basal insulin to a fixed ratio combination with a GLP-1 receptor agonist was associated with a 2.35 kg reduction in body weight in a pooled analysis.

    In plain wordsIn people with diabetes, switching from basal insulin to an insulin plus GLP-1 drug combination was linked to lower body weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change after switch from basal insulin to fixed ratio combination
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Switch from basal insulin to fixed ratio combinations with a glucagon like peptide 1 receptor agonist was associated
    2 context sentences
    Summary · context
    and 2.35 kg reduction in body weight (95% confidence interval -3.52 to -1.19; I 2 = 93%)
    Summary · context
    We conducted a systematic review and meta-analysis of randomised controlled trials to investigate the efficacy and safety of fixed ratio combinations of basal insulin with glucagon like peptide 1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with diabetes, switching from basal insulin to a fixed ratio combination with a GLP-1 receptor agonist reduced the risk of hypoglycaemia in a pooled analysis.

    In plain wordsIn people with diabetes, switching from basal insulin to an insulin plus GLP-1 drug combination was linked to less low blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia risk after switch from basal insulin to fixed ratio combination
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Switch from basal insulin to fixed ratio combinations with a glucagon like peptide 1 receptor agonist was associated
    2 context sentences
    Summary · context
    reducing also risk for hypoglycaemia [odds ratio 0.70; 95% confidence interval 0.57 to 0.86; I 2 = 85%]
    Summary · context
    We conducted a systematic review and meta-analysis of randomised controlled trials to investigate the efficacy and safety of fixed ratio combinations of basal insulin with glucagon like peptide 1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with diabetes, switching from basal insulin to a fixed ratio combination with a GLP-1 receptor agonist increased the incidence of nausea in a pooled analysis.

    In plain wordsIn people with diabetes, switching from basal insulin to an insulin plus GLP-1 drug combination was linked to more nausea.

    Peptide
    Liraglutide
    Outcome
    IncreaseNausea incidence after switch from basal insulin to fixed ratio combination
    Study

    n: not reported in source

    Comparator
    Basal insulin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Switch from basal insulin to fixed ratio combinations with a glucagon like peptide 1 receptor agonist was associated
    2 context sentences
    Summary · context
    but increasing incidence of nausea (odds ratio 6.89; 95% confidence interval 3.73-12.74; I 2 = 79%)
    Summary · context
    We conducted a systematic review and meta-analysis of randomised controlled trials to investigate the efficacy and safety of fixed ratio combinations of basal insulin with glucagon like peptide 1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with diabetes, switching from a GLP-1 receptor agonist to a fixed ratio combination with basal insulin was associated with a 0.94% reduction in haemoglobin A1c.

    In plain wordsIn people with diabetes, switching from a GLP-1 drug to a GLP-1 plus basal insulin combination was linked to lower HbA1c.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change after switch from GLP-1 receptor agonist to fixed ratio combination
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonist
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Similarly, switching patients from treatment with a glucagon like peptide 1 receptor agonist to a fixed ratio combination with basal insulin was associated with 0.94% reduction in haemoglobin A1c (95% confidence interval -1.11 to -0.77) and an increase in body weight by 2.89 kg (95% confi…
    1 context sentence
    Summary · context
    We conducted a systematic review and meta-analysis of randomised controlled trials to investigate the efficacy and safety of fixed ratio combinations of basal insulin with glucagon like peptide 1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with diabetes, switching from a GLP-1 receptor agonist to a fixed ratio combination with basal insulin was associated with a 2.89 kg increase in body weight.

    In plain wordsIn people with diabetes, switching from a GLP-1 drug to a GLP-1 plus basal insulin combination was linked to weight gain.

    Peptide
    Liraglutide
    Outcome
    IncreaseBody weight change after switch from GLP-1 receptor agonist to fixed ratio combination
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonist
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Similarly, switching patients from treatment with a glucagon like peptide 1 receptor agonist to a fixed ratio combination with basal insulin was associated with 0.94% reduction in haemoglobin A1c (95% confidence interval -1.11 to -0.77) and an increase in body weight by 2.89 kg (95% confi…
    1 context sentence
    Summary · context
    We conducted a systematic review and meta-analysis of randomised controlled trials to investigate the efficacy and safety of fixed ratio combinations of basal insulin with glucagon like peptide 1 receptor agonists.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.